The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors.
N. C. Tebbutt
Consultant or Advisory Role - Amgen (U)
Research Funding - Amgen
L. R. Lipton
No relevant relationships to disclose
T. J. Price
Consultant or Advisory Role - Amgen (U)
N. D. Belman
No relevant relationships to disclose
R. V. Boccia
Consultant or Advisory Role - Amgen
Stock Ownership - Amgen
Research Funding - Amgen
H. Hurwitz
Consultant or Advisory Role - Amgen
Research Funding - Amgen
J. Stephenson
Research Funding - Amgen
L. J. Wirth
Consultant or Advisory Role - Amgen
Honoraria - Amgen
S. McCoy
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
R. Sikorski
Employment or Leadership Position - Amgen; Amgen (I)
Stock Ownership - Amgen; Amgen (I)
Y. J. Hei
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
L. S. Rosen
Research Funding - Amgen